Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06124547
Other study ID # AS/CJ/ABR-22/0014
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date January 16, 2023
Est. completion date February 13, 2023

Study information

Verified date November 2023
Source Galenicum Health
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study was to evaluate and compare the bioavailability and therefore to assess the bioequivalence of two different formulations of sitagliptin/metformin extended release tablets after a single oral dose administration under fed conditions.


Recruitment information / eligibility

Status Completed
Enrollment 48
Est. completion date February 13, 2023
Est. primary completion date February 13, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: 1. Healthy adult male and female subjects aged = 18 and = 55 years. 2. Subjects is a non-or ex-smoker (An ex-smoker is defined as someone who completely stopped smoking for at least 6 months before screening). 3. With a weight = 50.00 kg. 4. With a body mass index (BMI) = 18.5 kg/m2 and = 27.0 kg/m2. This BMI range covers both COFEPRIS (18.0 to 27.0 kg/m2) and GCC (18.5 to 30.0 kg/m2) requirements. 5. Found healthy according to the clinical laboratory results and physical examination (performed within 28 days prior to the dosing on period 1). 6. Have a normal 12-lead ECG and vital signs. 7. Have laboratory test results within the laboratory's stated normal range; if not within this range, they must lack of clinical significance as judged by the PI or responsible physician. 8. If the subject of the study is female and childbearing potential / fertile (a woman is considered fertile from first menstruation and until she becomes postmenopausal, or permanently sterile), and agrees to use ANY ONE of the following forms of effective contraception / birth control (but not limited to) from the time of enrollment into the study and until at least 7 days after the last study drug administration, as judged by the PI considering the pharmacology of IP(s): 1. Established use of oral, transdermal, injected or subdermal implanted hormonal methods. 2. Intrauterine device (IUD or intrauterine system (IUS). 3. Barrier methods: e.g., diaphragm, cervical cap or condom (male or female condom). 4. Spermicidal: e.g., spermicidal foam, sponges or film. 5. Undergone bilateral tubectomy. 6. Accept to remain abstinent: When this is in line with the preferred and usual lifestyle of the subject. [Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception] OR Women who are postmenopausal (defined as female with no menses at least for the last 12 months without any medical cause) or permanently sterilized (e.g., undergone hysterectomy, bilateral salpingectomy or oophorectomy at least for the last 3 months). 9. If the subject of the study is male, he must be willing to use ANY ONE of the following forms of effective contraception / birth control (but not limited to) and willing not to donate sperm; from the time of enrollment into the study and until at least 7 days after the last study drug administration, as judged by the PI; 1. Willing to remain abstinent: When this is in line with the preferred and usual lifestyle of the subject. 2. Willing to use a male condom. 3. Male sterilization (men who have had vasectomy, at least 3 months previous to drug administration). 10. Subject able to communicate effectively and voluntarily agreed to participate in this study by signing written informed consent after being informed sufficiently about study aspects like objectives, study procedures, characteristics of the investigational drug, expected adverse events. 11. Subject willing to adhere to protocol requirements as evidenced by signing the informed consent form approved by the REC & RC. Exclusion Criteria: 1. Have any history of allergy or hypersensitivity to sitagliptin and metformin or to any of its metabolites/derivatives or related drugs or excipients. 2. Have a positive test result for HBs Ag or HCV Ab or HIV antibodies (types 1 and 2) or VDRL. 3. The study drug is contraindicated for medical reasons for the subject. 4. Have any history or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, hematological, neurological or psychiatric disease or disorder (e.g., subjects with uncontrolled hypertension, phaeochromocytoma, carcinoid, thyrotoxicosis, bipolar depression, schizoaffective disorder and acute confusional states) as judged by the PI considering the pharmacology of IP(s). 5. Presence of gastrointestinal, hepatic or kidney disease, or surgery or any other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs or known to potentiate or predispose to undesired effects. Or Subjects with a history of gastrointestinal disorder or surgery which may affect the absorption of investigational drug. 6. Have history or presence of Corona Virus Disease (COVID-19) during the last 30 days prior to dosing of period 1. Or Have history of vaccination (any dose) for COVID-19 during the last 14 days prior to dosing of period 1. Or Any planned vaccination for COVID-19 during the study period. 7. Have history or presence of cancer. 8. Have a history or evidence of drug abuse or alcohol abuse. 9. Have a history of smoking cigarettes during the last 6 months prior to screening. 10. Have any history of gastrointestinal ulcers / bleeding. 11. Have difficulty in swallowing solid medications such as tablet. 12. Have a history or evidence of difficulty with donating blood. 13. Have clinically significant abnormal laboratory tests results. 14. Have a systolic blood pressure < 90 or > 140 mmHg or diastolic blood pressure is < 60 or > 90 mmHg 15. Have a pulse rate less than 60 bpm or greater than 100 bpm (lower range will be accepted up to 45 bpm in case of athlete). 16. Have used any prescribed medication during the last 14 days preceding the first dosing, or use OTC, herbal products during the last 7 days or use medicinal enzyme inhibitors / inducers during 30 days preceding the first dosing. 17. Have participated in a drug research study the last 3 months or donated blood within the last 3 months. 18. Have a positive result for the alcohol test (breath / saliva) or drugs of abuse test [Cannabinoids (Marijuana/Tetrahydrocannabinol-THC), Cocaine, Opiates/Morphine, Amphetamine, Methamphetamine and Benzodiazepines] performed during screening. 19. Female subject, who is currently breast feeding or a who is pregnant or who is likely to become pregnant during the study. 20. Female subject has a positive pregnancy test result. 21. Unwillingness or inability to comply with the instructions on the restrictions and/or study procedures described in this Protocol. 22. If the PI considers, for any reason, that the volunteer is not a suitable candidate to receive the study drug.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Sitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet
The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet (Test or reference)

Locations

Country Name City State
Mexico Avant Santé Research Center S.A. de C.V. San Pedro Garza Garcia Nuevo León

Sponsors (1)

Lead Sponsor Collaborator
Galenicum Health

Country where clinical trial is conducted

Mexico, 

Outcome

Type Measure Description Time frame Safety issue
Primary Peak Plasma Concentration (Cmax) Evaluation of Peak Plasma Concentration (Cmax) 48 hours
Primary Area under the plasma concentration versus time curve (AUC) 0-t Evaluation of Area Under Plasma Concentration-Time Curve from Time Zero to the Last Measurable Concentration 48 hours
Primary Area under the plasma concentration versus time curve (AUC) 0-inf (Metformin only) Area Under Plasma Concentration-Time Curve from Time 0 to Infinite 48 hours
Secondary Number of participants with adverse events (AEs) To evaluate the safety and tolerability of a single oral dose of Sitagliptin /Metformin extended-release film coated tablets 50 mg /500 mg (FDC) under fed conditions 1 week
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05666479 - CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
Completed NCT05647083 - The Effect of Massage on Diabetic Parameters N/A
Active, not recruiting NCT05661799 - Persistence of Physical Activity in People With Type 2 Diabetes Over Time. N/A
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Completed NCT02836704 - Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose) Phase 4
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Completed NCT04562714 - Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy N/A
Completed NCT02009488 - Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT05896319 - Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2 N/A
Recruiting NCT05598203 - Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes N/A
Completed NCT05046873 - A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People Phase 1
Terminated NCT04090242 - Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes N/A
Completed NCT04030091 - Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus Phase 4
Completed NCT03604224 - A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
Completed NCT03620357 - Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D) N/A
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT03620890 - Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy Phase 4
Withdrawn NCT05473286 - A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Completed NCT04531631 - Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes Phase 2